Clinical Trial Update: Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors [NA]

View source ↗

Summary

Clinical trial update on Lu-DOTATATE treatment for somatostatin receptor–positive neuroendocrine tumors; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• 68Ga-DOTATATE (Gallium-68 DOTATATE)
• Lu-DOTATATE (Lutetium-177 DOTATATE)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Neuroendocrine Tumors | NA | Status: ACTIVE_NOT_RECRUITING